Brief: Aptose Reports Results For The Fourth Quarter And Full Year 2021
March 22 (Reuters) - Aptose Biosciences Inc APS.TO :
* APTOSE REPORTS RESULTS FOR THE FOURTH QUARTER AND FULL
YEAR 2021
* CASH RUNWAY INTO Q4 OF 2023
* ON TRACK TO INITIATE GENOTYPE-ENRICHED EXPANSION PROGRAM
FOR
HM43239 IN 2H22
* Q4 LOSS PER SHARE C$0.27
Source text for Eikon: ID:nGNX9S4FLB
Further company coverage: APS.TO
((reuters.briefs@thomsonreuters.com;))
Recent news on Aptose Biosciences
See all newsBrief: Aptose Biosciences Says Closing Of Arrangement With Hanmi Pharmaceutical Further Delayed
Brief: Aptose Reports First Quarter 2026 Results
Brief: Leading Independent Proxy Advisory Firm Glass Lewis Endorses Aptose Plan Of Arrangement
Brief: Leading Independent Proxy Advisory Firm Iss Recommends Aptose Biosciences Shareholders Vote “For” Proposed Plan Of Arrangement With Hanmi Pharmaceutical
Brief: Aptose Biosciences Announces Amendment To Arrangement Agreement And Details Of Shareholders Meeting